Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent chloride channel in epithelial cells; recently, we identified it in mast cells. Previous work that we confirmed showed that interferon γ (IFNγ) down-regulated CFTR expression in epithelial cells (T84), but by contrast, we found that IFNγ up-regulated CFTR mRNA and protein expression in rat and human mast cells. IFNγ up-regulation of CFTR in mast cells was inhibited by p38 and extracellular signal-regulated kinase (ERK) kinase inhibitors but not a Janus tyrosine kinase (JAK)2 inhibitor, whereas in T84 cells IFNγ-mediated down-regulation of CFTR was JAK2-dependent and ERK- and p38-independent. Furthermore, IFNγ down-regulation of CFTR in T84 epithelial cells was STAT1-dependent, but up-regulation of CFTR in mast cells was STAT1-independent. Thus, differential regulatory pathways of CFTR expression in mast cells and epithelial cells exist that depend upon either p38/ERK or JAK/STAT pathways, respectively. Surprisingly, IFNγ treatment of mast cells inhibited Cl- efflux, in contrast to up-regulation of CFTR/mRNA and protein expression. However, down-regulation of Cl- flux correlated with IFNγ-mediated inhibition of mediator secretion. This and other work suggests that the effect of IFNγ on CFTR expression in mast cells is important for their function.
Footnotes
-
This work was funded by grants to A.D.B. from the Canadian Institutes of Health Research (CIHR) and to M.D. from the Canadian Cystic Fibrosis Foundation. M.K. was supported by a student voucher from CIHR.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.087528.
-
ABBREVIATIONS: CFTR, cystic fibrosis transmembrane conductance regulator; PMC, rat peritoneal mast cell(s); ClC, voltage-gated Cl- channel; IFN, interferon; JAK, Janus tyrosine kinase; STAT, signal transduction and activator of transcription; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; TNF, tumor necrosis factor; AG-490, α-cyano-(3,4-dihydroxy)-N-benzylcinnamide tyrphostin B42; SB202190, C20H14FN3O; U0126, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)-butadiene); PMA, phorbol 12-myristate 13-acetate; HTB, HEPES Tyrode's buffer; MC, mast cell; RCMC, rat cultured mast cell(s); FBS, fetal bovine serum; LAD2, Laboratory of Allergic Diseases mast cell line 2; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; JNK, c-Jun NH2-terminal kinase; FAM, 6-carboxyfluorescein; BSA, bovine serum albumin; PCR, polymerase chain reaction; MQAE, N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide; IL, interleukin.
-
↵1 Current address: Allergy-Immunology Division, Feinberg School of Medicine, Northwestern University, Chicago, IL.
- Received April 5, 2005.
- Accepted July 26, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|